eGFR - 医索

找到约 375 条结果

首例：EGFR突变转移性尿路上皮癌奥希替尼五线治疗获长期缓解

本文报告了一名 48 岁的女性，没有明显的环境风险因素，确诊患有转移性尿路上皮癌（mUC），并且携带非小细胞肺癌的常见驱动突变EGFR突变。患者在一年内接受了四线尿路上皮癌标准疗法并出现了进展（包括肺、肝、骨和脑）。患者接受了奥希.....

学术资讯 - 临床研究

Subcutaneous amivantamab vs intravenous amivantamabboth in combination with lazertinib, in refractoryEGFR-mutated,advanced non-small cell lung cancer

医客学院 - 会议报告集

STRIKING THE BALANCE WITH NEXTGENERATION TARGETED THERAPIESFOR ALK AND EGFR

医客学院 - 会议报告集

Safety and efficacy of osimertinib plus consolidativestereotactic ablative radiation(SABR) inadvanced EGFR mutant non-small cell lungcancer(NSCLC)results from a multi-center Phase ltrial

医客学院 - 会议报告集

Molecular residual disease analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage lB-lllA non-small cell lung cancer

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

Amivantamab plus lazertinib vs osimertinib infirst-line EGFR-mutant advanced non-small cell lungcancer(NSCLC)with biomarkers of high-risk diseaseA secondary analysis from the phase 3 MARIPOSA study

医客学院 - 会议报告集

Amivantamab plus lazertinib in atypical EGFR-mutatedadvanced non-small cell lung cancer (NSCLC)Results from CHRYSALIS-2

医客学院 - 会议报告集

Amivantamab and lazertinib inpatients with EGFR-mutant lungcancers and CNS disease

医客学院 - 会议报告集

Adjuvant icotinib of 12 months or 6 months versus observationfollowing adjuvant chemotherapy for resected EGFR-mutatedstage ll-lllA non-small-cell lung cancer (ICTAN, GASTO1002) arandomized phase 3 trial

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
...
37
38
下一页
尾页

今日实时热搜